Cervical cancer development is driven by the transforming abilities of the human papillomavirus (HPV). Although the incidence of cervical cancer is fairly low in the United States due to the advent of the "pap" smear test and vaccination, 13,820 new cases and 4,360 deaths are projected in 2024 according to the NCI's Surveillance, Epidemiology, and End Results Program (SEER). The 5-Year relative survival rate is 67.4% (2014-2020). The Johns Hopkins University Cervical Specialized Program of Research Excellence (SPORE) was first funded in 2013, and its major activities are focused on the development of the next generation of novel preventive and therapeutic vaccines to improve treatment outcomes of patients with HPV-associated cervical cancer and its precursor lesions.
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
